Trial Profile
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Bifikafusp alfa/onfekafusp alfa (Primary)
- Indications Cancer metastases; Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms PIVOTAL
- Sponsors Philogen
- 05 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2024.
- 16 Oct 2023 Positive results from this study presented in a Philogen media release.
- 16 Oct 2023 According to a Philogen media release, The results will be presented at an upcoming international medical meeting and submitted to peer-reviewed journal, as well as to regulatory authorities.